Jeff Hall

Senior Editor, Diagnostic Imaging

Articles by Jeff Hall

Deep Learning Detection of Mammography Abnormalities: What a New Study Reveals

In multiple mammography datasets with the original radiologist-detected abnormality removed, deep learning detection of breast cancer had an average area under the curve (AUC) of 87 percent and an accuracy rate of 83 percent, according to research presented at the recent Society for Imaging Informatics in Medicine (SIIM) conference.

Expediting the Management of Incidental Pulmonary Emboli on CT

In a recent video interview from the Society for Imaging Informatics in Medicine (SIIM) conference, Ali Tejani, M.D., discussed pertinent insights on leveraging the value of adjunctive artificial intelligence (AI)-enabled triage software for computed tomography (CT) scans with radiology workflow improvements to achieve “clinically meaningful change” for patients with incidental pulmonary emboli findings.

PSMA PET Imaging May Offer Key Prognostic Markers for Prostate Cancer

For patients initially diagnosed with non-metastatic, castration-resistant prostate cancer, pelvic lymph node involvement and five or more polymetastases detected with prostate-specific membrane antigen (PSMA)/ positron emission tomography (PET) are significantly associated with lower overall survival rates, according to recently presented research at the American Society of Clinical Oncology (ASCO) conference.

Could Gamification Enhance Brain MRI Acquisition?

FIRMM-pix, a brain magnetic resonance imaging (MRI) software module recently launched at the International Society for Magnetic Resonance in Medicine (ISMRM) conference, reportedly employs visual biofeedback and gamification that coaches patients to stay still during brain MRI exams.

Stress Cardiovascular MRI: What a New Meta-Analysis Reveals

For the detection of obstructive coronary artery disease (CAD), stress cardiovascular magnetic resonance imaging (MRI) demonstrated a sensitivity rate of 81 percent and a specificity rate of 86 percent, according to a meta-analysis of 64 studies and data from 74,470 patients with stable chest pain.

MRI Findings Show Vorasidenib More Than Doubles Progression-Free Survival in Patients with Grade 2 IDH Gliomas

For patients with residual or recurrent grade 2 isocitrate dehydrogenase (IDH)-mutant gliomas, magnetic resonance imaging (MRI) revealed that daily dosing of vorasidenib, an inhibitor of mutant IDH1 and IDH2 enzymes, led to a median progression-free survival of 27.7 months in comparison to 11.1 months in a placebo group, according to new research presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

FDA Approves New PSMA PET Agent POSLUMA for Prostate Cancer Imaging

Reportedly the first FDA-approved PSMA PET agent with proprietary radiohybrid technology, POSLUMA can be utilized for positron emission tomography (PET) scans of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer and suspected metastasis, and those with suspected prostate cancer recurrence based on an elevated serum prostate-specific antigen (PSA) level.

Digital Mammography Meta-Analysis Says AI Performs as Well as Radiologists

Six reader studies on digital mammography revealed a pooled sensitivity rate of 80.8 percent for stand-alone artificial intelligence (AI) in comparison to 72.4 percent for radiologist assessment while seven historic cohort studies showed a 75.8 percent pooled sensitivity rate for stand-alone AI versus 72.6 percent for radiologist interpretation of digital mammography.